Key highlights

  • Optiscan Imaging shares traded at $0.125 at 11:04 AM AEDT on 19 November 2026, down 10.71%, while the S&P/ASX 200 was up 0.83% around midday.
  • Two US FDA 510(k) submissions were lodged for the InForm and InVue devices shortly after quarter end.
  • The company invested $1.957 million in Research and Development during the September 2026 quarter.

Shares in Optiscan Imaging Ltd (ASX:OIL) were trading at $0.125 during the session on 19 November 2026, down 10.71% at 11:04 AM AEDT, while the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. Optiscan is a medical imaging company that uses confocal laser endomicroscopy, with products for digital pathology, precision surgery and veterinary use. In its quarterly activities and cashflow report dated 30 October 2026, covering the quarter ended 30 September 2026, the company described the lodgement of two US FDA 510(k) submissions and the launch of its InSpecta product in the US veterinary market.

FDA Submissions for InForm and InVue

Optiscan lodged 510(k) submissions for its InForm digital pathology device and its InVue precision surgery device after the quarter end, following technical, clinical, testing and regulatory work during the quarter. The company describes these as among the most significant milestones in its recent history, moving its lead human-use platforms into formal FDA review. The submissions included validation work, risk management, quality documentation and comprehensive packages for both products.

Clinical Studies and Veterinary Launch

Optiscan signed two research agreements with the Mayo Clinic and started US breast cancer and head and neck cancer studies, designed to evaluate InVue and InForm in integrated surgical-pathology workflows. The InSpecta product was launched in the US veterinary market at the American Veterinary Medical Association convention in Anaheim, California, after its FDA dossier was lodged in the March 2026 quarter. Chief Executive Dr Camile Farah said the company is continuing to build the clinical and commercial foundations for these products.

Sector Context

FDA 510(k) clearance is a premarket pathway for devices that are substantially equivalent to products already on the market. Companies in digital pathology and surgical imaging typically face a long review period before commercial sales, and they depend on hospital and laboratory adoption once cleared.

Risks Investors Are Watching

The FDA review period is outside the company's control, and the submissions do not guarantee clearance. The company said there is still important work ahead, including Manufacturing readiness and commercial capability. Research and development spending is significant relative to the company's revenue, so funding needs remain a consideration.

What to Watch Ahead

Investors will be watching the FDA review process for both submissions, the results of the Mayo Clinic studies, the adoption of InSpecta in US veterinary practice and the company's next quarterly cashflow report.

About the Company

Optiscan Imaging Limited is an ASX-listed medical imaging company based in Mulgrave, Victoria, with a focus on confocal laser endomicroscopy. Its lead human-use platforms, InForm and InVue, are now under FDA review. The company reports its financial results in Australian dollars on an unaudited basis, and it describes its strategy as bringing together clinical evidence, manufacturing readiness and commercial capability.

Session Context

The shares were trading at $0.125 during the session on 19 November 2026, down 10.71% at 11:04 AM AEDT. These are intraday figures rather than a closing price, so the move reflects trade in progress at that time. Over the same period the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. In the previous session on 18 November, the Dow Jones closed down 1.32% and the Nasdaq closed down 0.02%. Trading conditions can change quickly during a session, so later moves may differ from the figures shown here.

Closing Note

Optiscan shares fell in mid-morning trade on 19 November 2026. The FDA review timetable and the Mayo Clinic study results will be the next material points for the company.